On March 27, 2018 -InteRNA Technologies reported that the company will present a poster on its lead microRNA development candidate INT-1B3 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in Chicago, IL, on April 14-18, 2018 (Press release, InteRNA Technologies, MAR 27, 2018, View Source [SID1234525017]). The proof-of-concept data highlight INT-1B3’s unique ability to target multiple hallmarks of cancer as a single agent, demonstrating immune system activation, tumor regression and pronounced long term immunity. InteRNA will announce the complete results through a press release following the presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Information:
Title: Pharmacologic profile of INT-1B3: a novel synthetic microRNA 193a-3p mimic for therapeutic intervention in Oncology (Abstract #4405)
Presenters: Drs. Sanaz Yahyanejad (Senior Research Scientist) and Michel Janicot (Chief Development Officer)
Session Name: Molecular and Cellular Biology / Genetics – MicroRNA Therapeutics
Date & Time: Tuesday, April 17, 2018; 1:00 pm -5:00 pm Central Standard Time
Location: McCormick Place South, Exhibit Hall A, Poster Section 19, Poster Board Number:6